CoChat

Elevated Lipoprotein(a) and Risk of Atrial Fibrillation

Open access
Mohammadi-Shemirani, Pedrum, Chong, Michael, Narula, Sukrit, Perrot, Nicolas, Conen, David, Roberts, Jason D., Thériault, Sébastien, Bossé, Yohan, Lanktree, Matthew B., Pigeyre, Marie, Paré, Guillaume · 2022 · Journal of the American College of Cardiology
Cited by 120

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Abstract

Atrial fibrillation (AF) is a cardiac arrhythmia associated with an elevated risk of stroke, heart failure, and mortality. However, preventative therapies are needed with ancillary benefits on its cardiovascular comorbidities. Lipoprotein(a) (Lp[a]) is a recognized risk factor for atherosclerotic cardiovascular disease (ASCVD), which itself increases AF risk, but it remains unknown whether Lp(a) is a causal mediator of AF independent of ASCVD. This study investigated the role of Lp(a) in AF and whether it is independent of ASCVD. Measured and genetically predicted Lp(a) levels were tested for association with 20,432 cases of incident AF in the UK Biobank (N = 435,579). Mendelian randomization analyses were performed by using summary-level data for AF from publicly available genome-wide association studies (N = 1,145,375). In the UK Biobank, each 50 nmol/L (23 mg/dL) increase in Lp(a) was associated with an increased risk of incident AF using measured Lp(a) (HR: 1.03; 95% CI: 1.02-1.04 ; P = 1.65 × 10–8) and genetically predicted Lp(a) (OR: 1.03; 95% CI: 1.02-1.05; P = 1.33 × 10–5). Mendelian randomization analyses using independent data replicated the effect (OR: 1.04 per 50 nmol/L Lp[a] increase; 95% CI: 1.03-1.05 per 50 nmol/L Lp[a] increase; P = 9.23 × 10–10). There was no evidence of risk-conferring effect from low-density lipoprotein cholesterol or triglycerides, and only 39% (95% CI: 27%-73%) of Lp(a) risk was mediated through ASCVD, suggesting that Lp(a) partly influences AF independent of its known effects on ASCVD. Our findings implicate Lp(a) as a potential causal mediator in the development of AF which show that the effects of Lp(a) extend across myocardial tissues. Ongoing clinical trials for Lp(a)-lowering therapies should evaluate effects on AF prevention.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jacc.2022.02.018

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Cited by

See all 120

Metadata

Authors
Mohammadi-Shemirani, P., Chong, M., Narula, S., Perrot, N., Conen, D., Roberts, J. D., Thériault, S., Bossé, Y., Lanktree, M. B., Pigeyre, M., & Paré, G.
Venue
Journal of the American College of Cardiology
Publisher
Elsevier BV
Published
2022-04
Volume
79
Issue
16
Pages
1579-1590
ISSN
0735-1097 (ISSN-L)
OpenAlex
W4224027734
Cited by
120
References
17
FWCI
16.48
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Elevated Lipoprotein(a) and Risk of Atrial Fibrillation. https://app.cochat.ai/papers/10.1016/j.jacc.2022.02.018
The paper
Mohammadi-Shemirani, P., Chong, M., Narula, S., Perrot, N., Conen, D., Roberts, J. D., Thériault, S., Bossé, Y., Lanktree, M. B., Pigeyre, M., & Paré, G. (2022). Elevated Lipoprotein(a) and Risk of Atrial Fibrillation. Journal of the American College of Cardiology. https://doi.org/10.1016/j.jacc.2022.02.018

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.